Collateral for a security interest recorded Feb 7, 2025 (Hayfin Services LLP).
Term ends Jul 20, 2035 · High confidence
20-year base term ends Jul 20, 2035
Held by Revance Therapeutics, Inc.
Filed Feb 26, 2018 as application 15/905,616 · Granted Nov 1, 2022
Base term plus 87 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2015
2035
Clock starts
Jul 20, 2015
Jul 20, 2015
Term ends
Jul 20, 2035
Jul 20, 2035
Granted
Nov 1, 2022
Nov 1, 2022
base term
fee events
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
87
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 9,901,627.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
2
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 87 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 20, 2015, when application 14/803,574, the earliest non-provisional in its chain, was filed (this one was filed Feb 26, 2018) | Jul 20, 2035 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +87 days, USPTO patent term adjustment record | Oct 15, 2035 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,901,627) | capped to Jul 20, 2035 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jul 20, 2035 | High confidence |
This family
| US 9,901,627 | In force Jul 2035 | Jul 2035 |
| US 11,484,580 | this patent Jul 2035 | Jul 2035 |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 18, 2022 Reel 59437, frame 654 | Revance Therapeutics, Inc. | Athyrium Buffalo LP | Security Interest |
| Mar 18, 2022 Reel 59436, frame 131 | Botulinum Toxin Research Associates, Inc. | Revance Therapeutics, Inc. | Assignment of Assignor's Interest |
| Mar 18, 2022 Reel 59439, frame 940 | Borodic, Gary E. | Botulinum Toxin Research Associates, Inc. | Assignment of Assignor's Interest |
| Feb 7, 2025 Reel 70153, frame 630 | Athyrium Buffalo LP | Revance Therapeutics, Inc. | Release of Security Interest |
| Feb 7, 2025 Reel 70153, frame 663 | Revance Therapeutics, Inc.; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 7, 2025 Reel 70153, frame 736 | Revance Therapeutics, Inc.; Bellus Medical, LLC; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 17, 2025 Reel 70239, frame 739 | Revance Therapeutics, Inc. | Jpmorgan Chase Bank, N.a. | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jul 2035
Term ends Jul 20, 2035. Maintenance fees still fall due before then
Note
The 87 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 9,901,627.
Citations
4
later US patents cite this one
That is above the median of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.